Recently, I was approached by a colleague who had seen a patient with type 1 diabetes using a glucagon-like peptide-1 receptor agonist in combination with basal bolus insulin to manage their glucose levels.
Finally available in Canada, the first epinephrine nasal spray certainly meets a public need, but will have to prove its worth to last, according to three experts interviewed by Profession Santé.
INESSS is updating its national medical protocol and group prescription template for medication adjustment and monitoring in adults with primary hypertension, and releasing a new guide for clinicians.